Investor Relations Contact: Argot Partners Sam Martin / Claudia Styslinger () [email protected] · [email protected] Recro Pharma, Inc. Form Q Recro Pharma, Inc. For: Sep 30 ; Operating lease asset. 5, ; Intangible assets, net. 5, ; Goodwill. 39, ; Other assets. ; Total assets. $. Recro Pharma, Inc. REPH, Pharmaceuticals, $, Presenting Acadia Healthcare Company, Inc. No, Yes, Gretchen, Hommrich, Director, Investor Relations. 2) In collaboration with Bayer 3) Partner: Tenax Therapeutics, Inc. 4) In collaboration with Janssen Pharmaceuticals 5) Partner: Recro Pharma, Inc. = Phase. (since April ) and Societal CDMO, Inc., formerly Recro Pharma, Inc. (since March ). Careers at Mallinckrodt · Community Outreach · Investor Relations.
Recro Pharma Inc (REPH) Stock in the last 5 years. 3 to 5 years is a preferred term of investing for some. Those investors can be called medium-term investors. Investor Relations, Recro Pharma Inc. EDUCATION. Georgetown University. Stanford University. BOARD MEMBERSHIPS. Palisade Bio Inc. Seneca Biopharma Inc. INDUSTRY. Recro assumes no obligation to update any such forward looking statements. CONTACT: Investor Relations Contact: Argot Partners Susan Kim/Natalie Wildenradt. Recro Pharma Stock Price (Quote) · Historical Recro Pharma prices · FAQ. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you. Recro Pharma Inc (NASDAQ: REPH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $ price. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of and. Recro Pharm receives Investment Bank Analyst Rating Update. An analyst The company was formerly known as Recro Pharma, Inc. and changed its name to. MALVERN, Pa., Sept. 10, (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on. Previous Name: Recro Pharma, Inc. Changed: 3/21/ Micro Cap Stock - Market Company's Investor Relations Information, Go to Investor Relations.
Altomari also serves on the board of directors of Recro Pharma, Inc. (Nasdaq View the latest Insmed Investor Presentation. Download. Primary Sidebar. CONTACT: Investor Relations Contact: Argot Partners Sam Martin / Claudia Styslinger () [email protected] · [email protected] Recro. Recro Pharma, Inc., a high-performing, revenue generating contract Investor Relations Contact: Argot PartnersSam Martin / Claudia Styslinger. company. She previously served on the boards of Recro Pharmaceuticals (NASDAQ:SCTL) from September to January and Catalent (NYSE:CTLT) from. Investor Relations Contact: Argot Partners. Claudia Styslinger. () [email protected] Recro Pharma, Inc. Ryan D. Lake. () Page. Investor Relations. Overview; News & Events. Back; Press Releases · Presentations Previously she was a member of the board of directors of Recro. Investor Relations Contact: Argot PartnersSam Martin / Claudia Styslinger() [email protected] [email protected] Recro Pharma, Inc. MALVERN, Pa., May 11, (GLOBE NEWSWIRE) -- Recro Pharma, Inc. Investor Relations Contact: Argot Partners Sam Martin / Claudia Styslinger. Therapeutics in June , as Chief Financial Officer (CFO). Most recently, he was the COO and previously the CFO of Recro Pharma, a specialty pharmaceutical.
Investors sometimes prefer comparable analysis of Recro Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Recro Pharma, Inc., or the Company, was incorporated in Pennsylvania on November 15, The Company is a revenue-generating, specialty pharmaceutical company. Recro Investor Group" or "Plaintiff"). (ECF 21 ¶ 1.) Defendant Recro • (5) Investor Relations Statements: Statements in press releases and on earnings. Recro Pharma, Inc. REPH, Pharmaceuticals, $, Presenting & Meetings VP, Investor Relations. , CytomX Therapeutics, Inc. Yes, Yes, Sean, McCarthy. 2) In collaboration with Bayer 3) Partner: Tenax Therapeutics, Inc. 4) In collaboration with Janssen Pharmaceuticals 5) Partner: Recro Pharma, Inc. = Phase.